换一批摘要Treatment for hepatocellular carcinoma(HCC)has been challenging as most patients present with late,advanced disease,where curative options are limited.For years,locoregional therapy(LRT)has been the first-line therapy for intermediate-stage HCC and sorafenib for advanced HCC.However,these treatments are often palliative since they are plagued by tumor recurrence or progression.Therefore,there is growing interest in combined therapy to utilize their respective strengths to produce synergistic effects.This review outlines past and current research on the efficacy and safety of combined LRT and systemic therapy.
更多相关知识
栏目名称
DOI
10.20517/2394-5079.2022.37
发布时间
2023-06-26（万方平台首次上网日期，不代表论文的发表时间）
- 浏览10
- 被引0
- 下载0
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
